Coston McIsaac & Partners’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.13M Sell
37,343
-1,679
-4% -$391K 2.06% 13
2025
Q4
$8.07M Buy
39,022
+663
+2% +$131K 1.87% 13
2025
Q3
$7.11M Buy
38,359
+1,614
+4% +$277K 1.69% 12
2025
Q2
$5.61M Buy
36,745
+205
+0.6% +$31.5K 1.45% 21
2025
Q1
$6.06M Buy
36,540
+2,268
+7% +$355K 1.77% 18
2024
Q4
$4.96M Sell
34,272
-3,211
-9% -$498K 1.47% 24
2024
Q3
$6.07K Buy
37,483
+924
+3% +$147K 1.71% 19
2024
Q2
$5.34M Buy
36,559
+2,403
+7% +$357K 1.68% 20
2024
Q1
$5.4M Buy
34,156
+774
+2% +$123K 1.74% 15
2023
Q4
$5.23M Buy
33,382
+973
+3% +$149K 1.82% 15
2023
Q3
$5.05M Buy
32,409
+1,343
+4% +$222K 1.91% 14
2023
Q2
$5.14M Buy
31,066
+781
+3% +$126K 1.77% 14
2023
Q1
$4.69M Buy
30,285
+1,437
+5% +$232K 1.75% 16
2022
Q4
$5.1K Buy
28,848
+1,523
+6% +$263K 1.98% 12
2022
Q3
$4.46M Buy
27,325
+2,315
+9% +$392K 2.04% 12
2022
Q2
$4.44M Buy
+25,010
New +$4.46M 2.68% 8

Other funds holding JNJ

Coston McIsaac & Partners's JNJ Position: Q1 2026 in Review

Coston McIsaac & Partners reduced its Johnson & Johnson (JNJ) stake by 4.3% in Q1 2026, selling an estimated $391K and leaving 37,343 shares worth $9.13M. The position accounts for 2.06% of the portfolio, ranked #13.

Coston McIsaac & Partners first reported a position in JNJ in Q2 2022 and has held it in 16 quarters since. 4,619 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Coston McIsaac & Partners held 37,343 shares of Johnson & Johnson worth $9.13M as of Q1 2026.
  • Coston McIsaac & Partners sold 1,679 Johnson & Johnson shares in Q1 2026, an estimated $391K.
  • Johnson & Johnson made up 2.06% of Coston McIsaac & Partners's portfolio in Q1 2026, its #13 holding.
  • Coston McIsaac & Partners first reported a position in Johnson & Johnson in Q2 2022 and has held it in 16 quarters since.
  • 4,619 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Coston McIsaac & Partners's 13F filing for Q1 2026, filed 22 Apr 2026.